Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, ...
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results